MedTrace Logo

Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)

NCT00857038 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-03-06

No results posted yet for this study

Summary

COPD is a progressive pulmonary disease that is characterized by an inflammatory process in the airways and the lungs which leads to progressive airway obstruction. The inflammation is associated with tissue loss and remodelling. The investigators hypothesized that doxycycline reduces neutrophilic airway inflammation in patients with COPD. Therefore the investigators will conduct a randomized trial of doxycycline in 30 patients.

Conditions

Interventions

DRUG

Doxycycline

Doxycycline tablets, 100mg daily

DRUG

Placebo

Placebo tablets 100mg

Sponsors & Collaborators

  • Leiden University Medical Center

    collaborator OTHER

  • University of Amsterdam

    collaborator OTHER

  • Medical Center Alkmaar

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-08-31
Completion
2010-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857038 on ClinicalTrials.gov